Azure Biosystems Inc.

Azure Biosystems Inc., a minority-owned for-profit corporation based in Dublin, California, manufactures and sells analytical laboratory imaging systems—gel documentation imagers, real-time PCR instruments, biomolecular imagers, and phosphor imaging systems—to federal research agencies and the Department of Veterans Affairs as a prime contractor on 99% of recent awards, with minimal subcontract exposure.

Azure Biosystems competes predominantly in the full-and-open market, not set-asides, though a small fraction of awards carry Total Small Business designations. The company's concrete capability portfolio centers on specialized scientific instrumentation: Azure 300, 400, and 600 imaging systems for gel electrophoresis and western blotting; Azure Cielo and Cielo 6 real-time PCR systems; the Sapphire and Sapphire FL biomolecular imagers; and phosphor imaging platforms. Representative prime work includes a $79,185.90 purchase order from the National Institute of Standards and Technology (August 2022) for a phosphor imaging system with four maintenance years, a $52,466.75 award from the National Cancer Institute (September 2024) for a Sapphire FL biomolecular imager, a $44,616 premium service contract from the CDC Pittsburgh (August 2023) for Azure Sapphire support running through March 2028, and a $40,700 multi-year services agreement with the Department of Veterans Affairs Veterans Integrated Service Network 20 (September 2023) for Sapphire imager support extending through September 2028.

Customer concentration runs heavy toward research and diagnostic agencies within the Department of Health and Human Services. The National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, and CDC Pittsburgh account for 36% of awards by count, with CDC Pittsburgh and NIAID anchoring the top rankings by potential value at $207 thousand and $168 thousand respectively. The CDC Pittsburgh, National Institute on Drug Abuse, and Agricultural Research Service Pacific West Area round out the top five. Azure Biosystems operates across 32 distinct federal customer agencies, with no dominant customer accounting for a disproportionate share—the portfolio reflects a fragmented, transaction-based business model driven by individual equipment purchases rather than large blanket awards or multi-year prime relationships.

Azure Biosystems places no task orders on government-wide IDIQs or GWACs; the source identifies one indefinite-delivery vehicle (75N91019D00038) carrying one task order. All seventy-five awards are small-value purchase orders, ranging from $9,342 to $79,185.90, typical of direct equipment procurement rather than program or vehicle-based work.

Activity contracted sharply: seventeen awards in 2022, declining to twelve in 2023, eleven in 2024, and dropping to three in 2025 and three in 2026 year-to-date. Six awards carrying $228 thousand in combined potential value face ultimate completion within the next twenty-four months, presenting moderate recompete exposure for the vendor but not a cliff. The vendor's footprint is concentrated in NAICS 541512 (Analytical Laboratory Instrument Manufacturing), which represents 48 of 75 awards, with secondary exposure in miscellaneous manufacturing. PSC coding clusters 55 awards under Laboratory Equipment and Supplies, confirming the instrument-centric business.

Azure Biosystems' subcontract activity is negligible—one sub-award on record from May 2024, where Roche Diagnostics Corporation (prime) subcontracted Azure Biosystems to deliver capital equipment supporting COVID-19 serology testing services. The vendor operates as a pure manufacturer and direct supplier to federal labs and medical centers, not as a systems integrator or systems contractor with meaningful teaming or prime-sub relationships.